Table 3 Follow-up studies on seropositive patients
From: Autoantibodies against retinal proteins in paraneoplastic and autoimmune retinopathy
Patients | Antibody Testing | ||||||
|---|---|---|---|---|---|---|---|
Number | Sex | Age | Specificity at onset of vision loss | Diagnosis of cancer | No. of Samples | No. of positive | After treatment |
P409 | M | 64 | Recoverin | Before | 11 | See Fig. 3 | Negative after chemotherapy and radiation |
P785 | M | 66 | Recoverin | 5 years after | 2 | 2 | |
P536 | F | 72 | Recoverin | Before | 2 | 2 | |
P718 | F | 64 | Recoverin | 6 months after | 8 | See Fig. 3 | Reduction after Rituxan |
P626 | F | 73 | Recoverin | 2 years after | 5 | 2 | |
P426 | F | 66 | Recoverin | After | 34 | See Fig. 3 | Negative after Tolpa [29] |
P570 | M | 72 | Recoverin | Before | 2 | 1 | |
P692 | M | 58 | P35 | 9 months after | 2 | 1 | Negative after systemic steroids |
P613 | M | 68 | P35 | Before | 2 | 2 | |
P566 | M | 59 | P35 | Before | 3 | 2 | Negative after INFa/b |
P559 | F | 51 | Bipolar cells | After | 3 | 1 | Negative after chemotherapy [13] |
P561 | F | 55 | Enolase | 3 months after | 5 | 5 | Reduction after IVIG |
P474 | F | 35 | Enolase | Before | 3 | 1 | |
P593 | F | 46 | Enolase | 17 years after | 2 | 2 | |
P660 | F | 65 | Enolase | No cancer | 3 | 2 | |
P436 | M | 43 | IPL | No cancer | 19 | 8 | Negative after IVIG |
P662 | F | 47 | P35, p46 | No cancer | 2 | 2 | |
P580 | M | 54 | P53, p46 | No cancer | 3 | 3 | No change after oral steroids |
P630 | M | 40 | P35 | No cancer | 2 | 2 | |
P579 | M | 30 | P35 | No cancer | 6 | 4 | No change after oral steroids |
P513 | F | 52 | Carbonic anhydrase | No cancer | 2 | 2 | |
P577 | M | 68 | P40 | No cancer | 2 | 2 | |
P623 | F | 34 | Arrestin | No cancer | 2 | 2 | |
P653 | F | 28 | P52 | No cancer | 3 | 3 | |